Upstream Bio (UPB) Preferred Dividend Payments (2023 - 2024)
Upstream Bio (UPB) posted quarterly Preferred Dividend Payments of $548000.0 for Q4 2024, down 82.61% year-over-year from $3.2 million in Q1 2024, and down 89.13% quarter-over-quarter from $5.0 million in Q3 2024.
Powered by 
Analysis
Upstream Bio (UPB) Preferred Dividend Payments (2023 - 2024) Analysis & Trends
Upstream Bio's Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at $548000.0 for Q4 2024.
- In Q4 2024, Preferred Dividend Payments fell 82.61% year-over-year to $548000.0; the TTM figure through Dec 2025 stood at $548000.0 (down 95.97% YoY), while the FY2024 annual figure was $13.6 million, down 23.3% from the prior year.
- Preferred Dividend Payments for Q4 2024 stood at $548000.0, down from $5.0 million in the prior quarter.
- The five-year high for Preferred Dividend Payments was $5.0 million in Q3 2024, with the low at $548000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 10 | Upstream Bio | 332.37 Mn | 332.37 Mn | -3.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 548,000.00 |
| Sep 30, 2024 | 5.04 Mn |
| Jun 30, 2024 | 4.88 Mn |
| Mar 31, 2024 | 3.12 Mn |
| Dec 31, 2023 | 3.15 Mn |
| Sep 30, 2023 | 3.15 Mn |